US Patent

US9439906 — Dosing regimen associated with long acting injectable paliperidone esters

Method of Use · Assigned to Janssen Pharmaceutica NV · Expires 2031-01-26 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating patients with long-acting injectable paliperidone palmitate formulations.

USPTO Abstract

The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2758 — Invega Sustenna
U-2758 — Invega Sustenna
U-2757 — Invega Sustenna
U-2758 — Invega Sustenna
U-2757 — Invega Sustenna

Patent Metadata

Patent number
US9439906
Jurisdiction
US
Classification
Method of Use
Expires
2031-01-26
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.